Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition

Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition — Live Feedhttps://www.live-feeds.com/feed/analysts-extremely-bullish-as-telix-beams-into-novartis-territory-with-1-6b-itm-acquisitionContinuously updated, source-cited coverage. Telix acquires ITM to expand radiopharmaceutical footprinthttps://www.live-feeds.com/feed/analysts-extremely-bullish-as-telix-beams-into-novartis-territory-with-1-6b-itm-acquisitionhttps://www.live-feeds.com/feed/analysts-extremely-bullish-as-telix-beams-into-novartis-territory-with-1-6b-itm-acquisition#u81769Wed, 23 Sep 2026 20:26:07 +0000Telix is acquiring Germany-based radioisotope maker ITM to establish a radiopharmaceutical powerhouse. While some reports value the deal at $1.6B or $1.65B, other sources state the merger is worth up to $2.35B. Analysts express extreme bullishness regarding the move, which positions Telix to compete in territory previously dominated by Novartis. The merger follows a surprise FDA rejection received by one of the involved companies.Why it mattersRadiopharmaceuticals combine targeted molecules with radioactive isotopes to treat or image diseases. This acquisition allows Telix to secure its isotop